Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 192

1.

Reinduction platform for children with first marrow relapse of acute lymphoblastic Leukemia: A Children's Oncology Group Study[corrected].

Raetz EA, Borowitz MJ, Devidas M, Linda SB, Hunger SP, Winick NJ, Camitta BM, Gaynon PS, Carroll WL.

J Clin Oncol. 2008 Aug 20;26(24):3971-8. doi: 10.1200/JCO.2008.16.1414. Erratum in: J Clin Oncol. 2008 Oct 1;26(28): 4697..

2.

Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.

Thomson B, Park JR, Felgenhauer J, Meshinchi S, Holcenberg J, Geyer JR, Avramis V, Douglas JG, Loken MR, Hawkins DS.

Pediatr Blood Cancer. 2004 Oct;43(5):571-9.

PMID:
15382275
3.

Novel multiagent chemotherapy for bone marrow relapse of pediatric acute lymphoblastic leukemia.

Leahey AM, Bunin NJ, Belasco JB, Meek R, Scher C, Lange BJ.

Med Pediatr Oncol. 2000 May;34(5):313-8.

PMID:
10797352
4.

Augmented therapy improves outcome for pediatric high risk acute lymphocytic leukemia: results of Children's Oncology Group trial P9906.

Bowman WP, Larsen EL, Devidas M, Linda SB, Blach L, Carroll AJ, Carroll WL, Pullen DJ, Shuster J, Willman CL, Winick N, Camitta BM, Hunger SP, Borowitz MJ.

Pediatr Blood Cancer. 2011 Oct;57(4):569-77. doi: 10.1002/pbc.22944. Epub 2011 Feb 25.

5.

Outcome of Reinduction Chemotherapy with a Modified Dose of Idarubicin for Children with Marrow-Relapsed Acute Lymphoblastic Leukemia: Results of the Childhood Acute Lymphoblastic Leukemia (CALL)-0603 Study.

Koh KN, Im HJ, Kim H, Kang HJ, Park KD, Shin HY, Ahn HS, Lee JW, Yoo KH, Sung KW, Koo HH, Lim YT, Park JE, Park BK, Park HJ, Seo JJ.

J Korean Med Sci. 2017 Apr;32(4):642-649. doi: 10.3346/jkms.2017.32.4.642.

6.

Bone marrow transplantation versus prolonged intensive chemotherapy for children with acute lymphoblastic leukemia and an initial bone marrow relapse within 12 months of the completion of primary therapy: Children's Oncology Group study CCG-1941.

Gaynon PS, Harris RE, Altman AJ, Bostrom BC, Breneman JC, Hawks R, Steele D, Zipf T, Stram DO, Villaluna D, Trigg ME.

J Clin Oncol. 2006 Jul 1;24(19):3150-6. Epub 2006 May 22.

PMID:
16717292
7.

Effectiveness of intensified rotational combination chemotherapy for late hematologic relapse of childhood acute lymphoblastic leukemia.

Rivera GK, Hudson MM, Liu Q, Benaim E, Ribeiro RC, Crist WM, Pui CH.

Blood. 1996 Aug 1;88(3):831-7.

8.

Treatment of late bone marrow relapse in children with acute lymphoblastic leukemia: a Pediatric Oncology Group study.

Sadowitz PD, Smith SD, Shuster J, Wharam MD, Buchanan GR, Rivera GK.

Blood. 1993 Feb 1;81(3):602-9.

9.

Chemoimmunotherapy reinduction with epratuzumab in children with acute lymphoblastic leukemia in marrow relapse: a Children's Oncology Group Pilot Study.

Raetz EA, Cairo MS, Borowitz MJ, Blaney SM, Krailo MD, Leil TA, Reid JM, Goldenberg DM, Wegener WA, Carroll WL, Adamson PC; Children's Oncology Group Pilot Study.

J Clin Oncol. 2008 Aug 1;26(22):3756-62. doi: 10.1200/JCO.2007.15.3528.

10.

Clinical importance of minimal residual disease in childhood acute lymphoblastic leukemia.

Coustan-Smith E, Sancho J, Hancock ML, Boyett JM, Behm FG, Raimondi SC, Sandlund JT, Rivera GK, Rubnitz JE, Ribeiro RC, Pui CH, Campana D.

Blood. 2000 Oct 15;96(8):2691-6.

11.

Comparison of idarubicin to daunomycin in a randomized multidrug treatment of childhood acute lymphoblastic leukemia at first bone marrow relapse: a report from the Children's Cancer Group.

Feig SA, Ames MM, Sather HN, Steinherz L, Reid JM, Trigg M, Pendergrass TW, Warkentin P, Gerber M, Leonard M, Bleyer WA, Harris RE.

Med Pediatr Oncol. 1996 Dec;27(6):505-14.

PMID:
8888809
12.

[Treatment outcome of childhood standard-risk and median-risk acute lymphoblastic leukemia with CCLG-2008 protocol].

Liu X, Zou Y, Wang H, Chen X, Ruan M, Chen Y, Yang W, Guo Y, Liu T, Zhang L, Wang S, Zhang J, Liu F, Cai X, Qi B, Chang L, Zhu X.

Zhonghua Er Ke Za Zhi. 2014 Jun;52(6):449-54. Chinese.

PMID:
25190166
13.

High-risk childhood acute lymphoblastic leukemia in first remission treated with novel intensive chemotherapy and allogeneic transplantation.

Marshall GM, Dalla Pozza L, Sutton R, Ng A, de Groot-Kruseman HA, van der Velden VH, Venn NC, van den Berg H, de Bont ES, Maarten Egeler R, Hoogerbrugge PM, Kaspers GJ, Bierings MB, van der Schoot E, van Dongen J, Law T, Cross S, Mueller H, de Haas V, Haber M, Révész T, Alvaro F, Suppiah R, Norris MD, Pieters R.

Leukemia. 2013 Jul;27(7):1497-503. doi: 10.1038/leu.2013.44. Epub 2013 Feb 14.

PMID:
23407458
14.

Clinical significance of minimal residual disease in childhood acute lymphoblastic leukemia after first relapse.

Coustan-Smith E, Gajjar A, Hijiya N, Razzouk BI, Ribeiro RC, Rivera GK, Rubnitz JE, Sandlund JT, Andreansky M, Hancock ML, Pui CH, Campana D.

Leukemia. 2004 Mar;18(3):499-504.

PMID:
14981525
15.

Reinduction therapy in 297 children with acute lymphoblastic leukemia in first bone marrow relapse: a Pediatric Oncology Group Study.

Buchanan GR, Rivera GK, Boyett JM, Chauvenet AR, Crist WM, Vietti TJ.

Blood. 1988 Oct;72(4):1286-92.

16.

Intrathecal triple therapy decreases central nervous system relapse but fails to improve event-free survival when compared with intrathecal methotrexate: results of the Children's Cancer Group (CCG) 1952 study for standard-risk acute lymphoblastic leukemia, reported by the Children's Oncology Group.

Matloub Y, Lindemulder S, Gaynon PS, Sather H, La M, Broxson E, Yanofsky R, Hutchinson R, Heerema NA, Nachman J, Blake M, Wells LM, Sorrell AD, Masterson M, Kelleher JF, Stork LC; Children's Oncology Group.

Blood. 2006 Aug 15;108(4):1165-73. Epub 2006 Apr 11.

17.

Re-induction chemoimmunotherapy with epratuzumab in relapsed acute lymphoblastic leukemia (ALL): Phase II results from Children's Oncology Group (COG) study ADVL04P2.

Raetz EA, Cairo MS, Borowitz MJ, Lu X, Devidas M, Reid JM, Goldenberg DM, Wegener WA, Zeng H, Whitlock JA, Adamson PC, Hunger SP, Carroll WL.

Pediatr Blood Cancer. 2015 Jul;62(7):1171-5. doi: 10.1002/pbc.25454. Epub 2015 Mar 2.

18.

Treatment of CNS relapse in children with acute lymphoblastic leukemia: A Pediatric Oncology Group study.

Winick NJ, Smith SD, Shuster J, Lauer S, Wharam MD, Land V, Buchanan G, Rivera G.

J Clin Oncol. 1993 Feb;11(2):271-8.

PMID:
8426204
19.

Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.

Uckun FM, Stork L, Seibel N, Sarquis M, Bedros C, Sather H, Sensel M, Reaman GH, Gaynon PS.

Clin Cancer Res. 2000 Aug;6(8):3123-30.

20.

Minimal residual disease status before allogeneic bone marrow transplantation is an important determinant of successful outcome for children and adolescents with acute lymphoblastic leukemia.

Knechtli CJ, Goulden NJ, Hancock JP, Grandage VL, Harris EL, Garland RJ, Jones CG, Rowbottom AW, Hunt LP, Green AF, Clarke E, Lankester AW, Cornish JM, Pamphilon DH, Steward CG, Oakhill A.

Blood. 1998 Dec 1;92(11):4072-9.

Supplemental Content

Support Center